Curaleaf International Comments As German Federal Cannabis Law Passes Without Delay
2024年3月22日 - 11:53PM
ビジネスワイヤ(英語)
Today, it has been announced that the German Federal
Government's cannabis law, also known as Pillar 1, has successfully
progressed without delay. Following the positive outcome of the
vote in the German Bundestag on February 23, 2024, the legislation
has swiftly moved through subsequent stages of approval,
culminating in its enactment.
Juan Martinez, Head of Curaleaf International, a leading
cannabis company in Europe, commented:
"The successful passage of the Cannabis Act represents a
significant milestone in our journey towards destigmatisation and
decriminalisation of cannabis for both patients and consumers.
The removal of cannabis from the narcotics list and the
subsequent implementation of comprehensive regulations will not
only benefit patients and consumers but also pave the way for a
thriving and regulated cannabis market in Germany.
As a company deeply invested in the European cannabis landscape,
we are excited about the opportunities this legislation brings.
With a robust regulatory framework in place, we anticipate broader
insurance coverage, reduced administrative burdens for
prescriptions, and a substantial growth trajectory for both the
medical markets and eventually the regional model projects with
commercial supply chains. This growth, coupled with the potential
domino effect on other European markets, positions Germany as a
trailblazer in shaping the future of cannabis in Europe.
Curaleaf has strategically expanded its European footprint
through our Terra Verde facility in Portugal, leading UK clinic and
pharmacy, top German brand in Four 20 Pharma and strategic
acquisitions of Clever Leaves in Portugal, Can4Med in Poland, and
Northern Green Canada. Our full seed-to-sale process allows us
first mover advantage to meet the anticipated demand from a
thriving, regulated, and safe cannabis industry.
We remain committed to supporting the German market and
fostering an environment that prioritises patient well-being and
accessibility. Our dedication to advancing scientific research,
innovation, and responsible cultivation practices aligns with the
objectives of the Cannabis Act, and we are eager to contribute to
its successful implementation.”
About Curaleaf International
Curaleaf International is one of the largest vertically
integrated cannabis companies in Europe. Its unique supply and
distribution network throughout the European market brings together
pioneering science and research with cutting-edge cultivation,
extraction, and production. Amidst a rapid growth trajectory, the
emphasis on quality and expertise aims to ensure the delivery of
safe, reliable, and effective care for all.
Curaleaf International's subsidiary network includes Curaleaf
Clinic, Curaleaf Pharmacy, and Curaleaf Laboratories within the UK.
Additionally, it extends to Terra Verde cultivation facility in
Portugal, the Medalchemy research and development site in Spain,
the Four20 Pharma wholesaler and distributor in Germany, and the
Polish wholesaler Can4Med.
Curaleaf International is part of Curaleaf Holdings, Inc., a
leading global cannabis company. Curaleaf is listed on the TSX
(Toronto Stock Exchange) and trades on the OTCQX market under the
symbol CURLF.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240322195660/en/
Iskander Javed, Third City 07719939893
iskander@thirdcity.co.uk
Curaleaf (TSX:CURA)
過去 株価チャート
から 11 2024 まで 12 2024
Curaleaf (TSX:CURA)
過去 株価チャート
から 12 2023 まで 12 2024